Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression

Table 3 Association of cytochrome P450 3A5 polymorphism with tacrolimus trough level in expressors and non-expressors

Timeline	Expressors (n = 35) (mean ± SD)	Non-expressors (n = 60) (mean ± SD)	P value
Tacrolimus trough level (ng/mL)
At 5 days	7.6 ± 3.3	7.7 ± 3.2	0.8848
At 15 days	6.1 ± 3.0	6.8 ± 2.5	0.2249
At 30 days	6.0 ± 2.2	6.4 ± 2.0	0.3672
At 45 days	5.6 ± 2.2	6.2 ± 1.5	0.1180
At 90 days	6.7 ± 2.9	5.9 ± 2.6	0.1690
At 120 days	6.6 ± 1.9	6.1 ± 1.9	0.2191
At 6 months	6.7 ± 2.2	5.3 ± 1.2	0.001
At 9 months	6.5 ± 1.2	4.6 ± 1.2	< 0.001
At 12 months	6.2 ± 1.2	4.9 ± 0.7	< 0.001